Atlas Trials

A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.

Clinical trial NCT04999878 · UNKNOWN

Trial details

NCT number
NCT04999878
Sponsor
Zhengzhou University
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Hemophagocytic SyndromeT/NK-Cell Lymphoma
Start date
2021-05-30
Primary completion
2023-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.